Glofitamab plus PD‑1 antibody and lenalidomide for relapsed/refractory TP53‑aberrant large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single‑arm, open‑label Phase II trial giving glofitamab, a PD‑1 antibody, and lenalidomide to adults with relapsed or refractory CD20‑positive large B‑cell lymphoma and confirmed TP53 aberrations. The study uses a Simon two‑stage design with an initial cohort of 9 patients and a planned total enrollment of 24 if early efficacy thresholds are met. The primary endpoint is best complete response rate per 2014 Lugano criteria by FDG‑PET, and secondary endpoints include overall response rate, progression‑free survival, overall survival, duration of response, MRD negativity, and safety/tolerability. Treatment includes an induction period with premedication and scheduled imaging and labs to monitor response and adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent form before any study-specific procedures.
* Age ≥ 18 years at the time of consent.
* Histologically confirmed large B-cell lymphoma (LBCL) with CD20 expression, including but not limited to:Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS),Transformed follicular lymphoma (tFL),Grade 3B follicular lymphoma (3B FL),High-grade B-cell lymphoma (HGBCL),Intravascular large B-cell lymphoma (IVLBCL),Primary mediastinal large B-cell lymphoma (PMBCL),Epstein-Barr virus-positive LBCL (EBV+ LBCL).
* Relapsed or refractory (R/R) LBCL defined as:

Relapsed: Disease recurrence after achieving remission for longer than 6 months after completing the last line of therapy.

Refractory: Failure to achieve remission or progression within 6 months after completing the last line of therapy.

* Confirmed TP53 deletion or mutation via FISH or NGS.
* Not eligible for autologous stem cell transplantation (ASCT) per any of the following criteria: Age ≥ 70 years, End-stage organ dysfunction, ECOG performance status of ≥ 2,Patient decision to decline ASCT, Other investigator-determined comorbidities (e.g., severe heart or lung disease, active infections) per local clinical practice standards.
* Measurable disease at baseline, with at least:

One lymph node lesion ≥ 1.5 cm (in the longest diameter), or One extranodal lesion ≥ 1.0 cm (in the longest diameter).

* ECOG performance status of 0, 1, or 2.
* Life expectancy of ≥ 12 weeks, as assessed by the investigator.
* Adequate hematologic function unless due to extensive bone marrow involvement or spleen-related complications caused by lymphoma, defined as:

Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L,Platelets ≥ 50 × 10⁹/L,Hemoglobin ≥ 80 g/L.

-Willingness to adhere to the study procedures, including contraception requirements during the trial for participants of reproductive potential.

Exclusion Criteria:

* Prior allogeneic stem cell transplantation or organ transplantation. Active central nervous system involvement by lymphoma. Active autoimmune diseases requiring immune suppressive therapy. Uncontrolled systemic infections, including active hepatitis B, hepatitis C, or HIV infection.

Previous treatment with Glofitamab, another bispecific antibody targeting CD20 and CD3, or PD-1 inhibitors combined with Lenalidomide.

History of severe hypersensitivity to monoclonal antibodies or any components of the study drugs.

Concurrent participation in another investigational study. Use of systemic immunosuppressive therapy within 14 days prior to enrollment (excluding corticosteroids for lymphoma treatment or prevention of adverse effects).

Pregnant or breastfeeding women. Any psychological, social, or medical condition that, in the investigator's opinion, could interfere with study compliance or compromise the participants' safety or outcome.

Where it's running

• The First Affiliated Hospital with Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Wei Xu Doctor
• Email: xuwei10000@hotmail.com
• Phone: 86-2568302182

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

• Real-world outcomes with glofitamab for large B-cell lymphoma

  This project looks at how well glofitamab works and how safe it is for adults in France with relapsed or refractory large B‑cell lymphoma who were treated through the expanded access program.

  Recruiting at 30 sites The Lymphoma Academic Research Organisation · Argenteuil and 29 other locations · NCT06994169

• Combination of drugs for treating relapsed large B-cell lymphoma before and after CAR-T therapy

  This study is testing a combination of three drugs to see if they can help people with relapsed large B-cell lymphoma feel better before and after CAR-T therapy.

  Recruiting at 5 sites Phase 2 University College, London · London and 4 other locations · NCT06071871

• Hypofractionated Radiotherapy plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  This study tests a combination therapy—hypofractionated radiotherapy with GM-CSF, pomalidomide, and glofitamab—for adults newly diagnosed with primary CNS DLBCL to see if it helps control the disease.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07749365

• Glofitamab with R-CHOP for Newly Diagnosed HIV-Related Large B-Cell Lymphoma

  This phase 1 study tests glofitamab plus R-CHOP chemoimmunotherapy in adults newly diagnosed with HIV-related large B-cell lymphoma to see if the regimen is safe and tolerable.

  Recruiting Phase 1 National Cancer Institute (NCI) · Rockville, Maryland · NCT07649304

• Pola-ZR-Glo for older patients with large B‑cell lymphoma

  This trial will try combining polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab as first-line treatment for people aged 70 and older with newly diagnosed large B‑cell lymphoma who are unfit for standard chemo or decline immunochemotherapy.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07514169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.